"Since joining uniQure early in the year as a consultant, Christian has built an extremely experienced clinical development team. This team is operating already at a high level as our pipeline programs advance into further clinical evaluation in the next 12-24 months," said JÖrn Aldag, CEO of uniQure. "Christian's leadership in clinical development as well as his focus on rare diseases is a tremendous resource for the company and we are very glad to welcome him officially to the management team."
"I have been impressed with both the company's achievements in gaining approval for Glybera in the
uniQure is delivering on the promise of gene therapy, single treatments with potentially curative results. We have developed a modular platform to rapidly bring new disease modifying therapies to patients with severe disorders. Our approach is validated by multiple partnerships and the regulatory approval of our lead product Glybera. www.uniqure.com.
Press release (PDF): http://hugin.info/157414/R/1733550/580459.pdf
Jorn AldagCEO uniQure T: +31 20 566 8014 email@example.com Media inquiries: MacDougall Biomedical Communications Doug MacDougall(US) +1 781 235_3060 firstname.lastname@example.org Gretchen Schweitzer( Europe) +49 172 861 8540 email@example.com